Lux kicks off trial for uveitis treatment

Article

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211.

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211, a next-generation calcineurin inhibitor, for the treatment of uveitis.

The trial, LUMINATE (Lux Uveitis Multicentre Investigation of a New Approach to TreatmEnt), consists of three controlled, double masked studies investigating the use of LX211 in different forms of active uveitis and in maintaining control in patients with quiescent disease.

The company expects to enrol more than 500 patients at approximately 45 sites across North America, Europe and India. Efficacy will be measured at six months by assessing the degree of inflammation in the anterior and posterior segments of the eye.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.